Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01181479 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System
A Phase 3 study, sponsored by Agile Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,504
- Enrollment target
NCT01181479 is a Phase 3 study that has completed, run by Agile Therapeutics. The registered enrollment target is 1,504 participants.
The verdict
NCT01181479, a Phase 3 study, has completed, sponsored by Agile Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,504 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.
Interventions
- DRUG AG200-15 (cycles 1-13)
- DRUG Lessina crossover to AG200-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01181479
The ClinicalTrials.gov registry entry for NCT01181479 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agile Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AG200-15 (cycles 1-13) is the first listed.
NCT01181479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01181479 about?
NCT01181479 is a clinical study titled "Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System". The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.
What is the current status of trial NCT01181479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,504 participants. The study started on 2010-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01181479?
The interventions under investigation include: AG200-15 (cycles 1-13) (DRUG), Lessina crossover to AG200-15 (DRUG).
Who is sponsoring clinical trial NCT01181479?
This trial is sponsored by Agile Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.